• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endocare

Endocare

Endocan Corp ENDO

Last Price$0.02Day Change (%)-0.79%
Open Price$0.02Day Change ($)0.00
Day Range0.02–0.0252-Week Range0.02–0.18

As of Wed 11/26/2014 02:50 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Research and Markets: Australia General Surgery Market Outlook to 2020: Key players covered include Olympus, Ethicon, Covidien, B. Braun Melsungen, C.R. Bard, and KARL STORZ GmbH & Co

    Research and Markets: Australia General Surgery Market Outlook to 2020: Key players covered include Olympus, Ethicon, Covidien, B. Braun Melsungen, C.R. Bard, and KARL STORZ GmbH & Co

  2. Research and Markets: France General Surgery Market Outlook to 2020: Key players covered include Olympus, Ethicon, Covidien, B. Braun Melsungen, C.R. Bard, and KARL STORZ GmbH & Co

    Research and Markets: France General Surgery Market Outlook to 2020: Key players covered include Olympus, Ethicon, Covidien, B. Braun Melsungen, C.R. Bard, and KARL STORZ GmbH & Co

  3. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  4. NEC and Texas State University Sign MOU to Collaborate on Social Infrastructure Projects

    NEC and Texas State University Sign MOU to Collaborate on Social Infrastructure Projects

  5. Renesas Electronics Reports Financial Results for the Second Quarter Ended September 30, 2014

    Renesas Electronics Reports Financial Results for the Second Quarter Ended September 30, 2014

  6. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

    As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

  7. Our Outlook for the Credit Markets

    The corporate bond market will probably struggle to return much above break-even in 2014.

  8. Covidien's Mallinckrodt Spin-Off Faces Challenging Environment

    Mallinckrodt's lack of scale and weak branded business keep it from earning a moat.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.